Efficacy News and Research

RSS

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Clinical trials used by the Food and Drug Administration (FDA) to approve new drugs between 2005 and 2012 vary widely in their characteristics, according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Several potentially preventable deficiencies, including failure to select optimal drug doses and suitable outcome measures for a study, accounted for significant delays in the approval of new drugs by the Food and Drug Administration (FDA), according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Social cognitive deficits contribute to perpetuation of cocaine addiction, say scientists

In Europe as well as worldwide, cocaine is the second most frequently used drug after cannabis. Chronic cocaine users display worse memory performance, concentration difficulties, and attentional deficits but also their social skills are affected as previous studies at the Psychiatric Hospital of the University of Zurich suggested.

22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Dihydroartemisinin-piperaquine more effective than artemether-lumefantrine in treating malaria

'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.

21 Jan 2014

Daytime water restriction effective in nocturia

Researchers from Japan say that some men with nocturia should be advised to restrict their fluid intake during the day and not just at night.

20 Jan 2014

Technology increases cognitive behavioral therapy options for insomnia

Web- and telehealth-based delivery of cognitive behavioral therapy is effective for treating chronic insomnia, giving rural-dwelling adults more choice and better access to services, researchers report.

20 Jan 2014

Gene therapy edges closer for Parkinson’s disease

Lentiviral vector-based gene therapy is well tolerated and may improve motor function in patients with Parkinson’s disease, shows an open-label study published in The Lancet.

20 Jan 2014

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

A long-shot lawsuit that could have damaged the effectiveness of health care reform got a well-deserved brushoff from a federal district judge on Wednesday.

20 Jan 2014

Breakthrough technology could provide new approach for treatment of chronic wounds

A team of researchers led by an NIBIB grantee at Vanderbilt University has created a biodegradable scaffold that enables sustained, local delivery of gene-silencing factors called siRNA to promote tissue regeneration. The team recently used the scaffold to successfully deliver siRNA to mice in order to locally silence a gene normally responsible for inhibiting blood vessel formation.

20 Jan 2014

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.

20 Jan 2014

Large-scale HIV intervention project conducted by Penn Nursing at South Africa proves successful

A large-scale human immunodeficiency virus (HIV) intervention/education effort aimed at helping South African men take a proactive role in the prevention of that disease has proven successful, an important development considering that country has the largest number of HIV infections in the world.

20 Jan 2014

Poisonous bacteria may one day become useful tool for industry and environmental protection

Buried deep in the mud along the banks of a remote salt lake near Yosemite National Park are colonies of bacteria with an unusual property: they breathe a toxic metal to survive.

20 Jan 2014

Efficacy News and Research

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Social cognitive deficits contribute to perpetuation of cocaine addiction, say scientists

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Dihydroartemisinin-piperaquine more effective than artemether-lumefantrine in treating malaria

Daytime water restriction effective in nocturia

Technology increases cognitive behavioral therapy options for insomnia

Gene therapy edges closer for Parkinson’s disease

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Breakthrough technology could provide new approach for treatment of chronic wounds

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Large-scale HIV intervention project conducted by Penn Nursing at South Africa proves successful

Poisonous bacteria may one day become useful tool for industry and environmental protection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News